Molecular Pharmacology Program
The Daniel Heller Lab
Cancer Nanomedicine Laboratory
We are inventing novel technologies to treat advanced cancers and to detect disease at early stages. We are a young bioengineering laboratory that develops new nanotechnologies, including nanomedicines—tiny particles that target drugs to tumor sites, and nanosensors—tiny devices that detect markers of disease. Please check out our recent innovations using the “Learn more” button below…
J Budhathoki-Uprety, J Shah, JA Korsen, AE Wayne, TV Galassi, JR Cohen, JD Harvey, PV Jena, LV Ramanathan, EA Jaimes, DA Heller*. “Synthetic Molecular Recognition Nanosensor Paint for Microalbuminuria.” Nature Communications 10 (2019) 3605.
TV Galassi, PV Jena, J Shah, G Ao, E Molitor, Y Bram, A Frankel, J Park, J Jessurun, DS Ory, A Haimovitz-Friedman, D Roxbury, J Mittal, M Zheng, R E Schwartz, DA Heller*. “An Optical Nanoreporter of Endolysosomal Lipid Accumulation Reveals Enduring Effects of Diet on Hepatic Macrophages In Vivo.” Science Translational Medicine 10 (2018) eaar2680.
Y Shamay, J Shah, DF Tschaharganeh, D Roxbury, J Budhathoki-Uprety, M Işık, A Mizrachi, K Nawaly, JL Sugarman, E Baut, MR Neiman, DC Johnson, R Sridharan, KL Chu, VK Rajasekhar, JD Chodera, SW Lowe, DA Heller*, “Quantitative Self-Assembly Prediction Yields Targeted Nanomedicines” Nature Materials (2018)
Daniel A. Heller, PhD
- Chemist Daniel Heller focuses on biomaterials and nanoscale engineering for molecular sensors and targeted therapeutics.
- PhD, University of Illinois at Urbana-Champaign
- PhD in Engineering and Bioengineering
- American Cancer Society Research Scholar (2018)
- NSF CAREER Award (2018)
- Pershing Square Sohn Prize for Young Innovators in Cancer Research (2017)
- NIH Director’s New Innovator Award (2012)
- Damon Runyon Cancer Research Foundation Postdoctoral Fellowship (2010)
- Beckman Institute Graduate Fellowship (2006)
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Daniel A. Heller discloses the following relationships and financial interests:
Nirova BioSense, Inc.
Intellectual Property Rights; Ownership / Equity Interests
Provision of Services (uncompensated)
Zeno Pharmaceuticals, Inc.
Ownership / Equity Interests
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.